Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 6/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133149 | 0.90 | CNR1 (0.39) | SIGMAR1DRD2SMN1; SMN2NR3C1 | |
| SCHEMBL25634866 | 0.87 | PAOX (0.42) | HTR4SIGMAR1DRD2CYP1A2MAPK1 | |
| SCHEMBL25369363 | 0.82 | CYP1A2 (0.55) | HTR4SIGMAR1HRH3CYP1A2MAPK1 | |
| SCHEMBL7347272 | 0.80 | PLA2G10 (0.42) | HTR4NR3C1 | |
| SCHEMBL21946902 | 0.79 | MEN1 (0.42) | HTR4SIGMAR1CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL22608823 | 0.79 | SIGMAR1 (0.37) | HTR4SIGMAR1HRH3DRD2CYP1A2 | |
| SCHEMBL24966338 | 0.79 | SIGMAR1 (0.37) | HTR4SIGMAR1DRD2CYP1A2MAPK1 | |
| SCHEMBL10867514 | 0.79 | CYP1A2 (0.44) | HTR4CYP1A2 | |
| SCHEMBL22608846 | 0.78 | USP2 (0.46) | SIGMAR1SMN1; SMN2EPHX2 | |
| SCHEMBL27055101 | 0.78 | ALDH1A1 (0.46) | HTR4HRH3CYP1A2MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-2013197-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007102771-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | HTR4 146/4885SIGMAR1 1619/4885HRH3 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.